Skip to main content

Table 4 Patients with endoscopic inflammation involvement

From: Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis

Characteristic High-risk featuresa
N = 71
No high-risk features
N = 111
P value
Duration of symptoms (days, SD) 41 (106) 27 (60) 0.301
IV steroids, n (%) 41 (66.1) 42 (58.3) 0.378
Infliximab/vedolizumab, n (%) 30 (46.2) 12 (15.8) < 0.001
Mean duration from diagnosis to first recurrence (days, SD) 140 (147) 144 (121) 0.902
Outcomes, n (%)
 Hospitalization 58 (81.7) 74 (66.7) 0.028
 Duration of hospitalization (days, SD) 9 (8) 6 (5) 0.016
 ICU admission 3 (4.2) 4 (3.6) 0.656
 Recurrence 20 (28.2) 31 (27.9) 1.000
 Repeat endoscopy 18 (25.4) 18 (16.2) 0.181
  1. aHigh-risk endoscopic features; deep ulcers > 2 mm in depth, large ulcers > 1 cm, extensive involvement